Mostly Markets
Subscribe
Markets
S&P 500 ▼ 1.82%Nasdaq ▼ 2.86%Dow ▼ 1.09%Russell 2000 ▼ 1.66%10-year 4.93%Oil ▲ 0.93%Gold ▼ 3.63%Bitcoin ▲ 1.13%
Newest story
Stocks/Health Care/Health Care Equipment

Idexx LaboratoriesIDXX

Health Care Equipment · Westbrook, Maine · In the S&P 500
High qualityPricier than peers
$551.21−4.30%After hours: $538.70 (−2.27%)At the close, 30 Oct · Prices from CNBC, may be delayed
▼ 12.2% over 1 year
Idexx Laboratories over 1 yearDaily close, $, to 30 Oct 2026
$500$600$700Nov2026MarMayJulSep$551.21$500$600$700NovMarJul$551.21
Source: Nasdaq daily closes
Market value$43.42B
Price to earnings38.7x
Forward P/E35.1x
Dividend yield–
Year to date−18.5%
One year−12.2%
Next earningsMon 2 Nov, before the open
SectorHealth Care
52-week range (closes)
$504.70$766.68

The latest on Idexx Laboratories

Our stories first, then the headlines that could move it, newest first.

We haven't written about Idexx Laboratories yet. Follow it, and its first story will show under My stocks.

Quality and valuation

How Idexx Laboratories compares with other health care stocks. A description, not a recommendation.

Idexx Laboratories and 7 health care equipment peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: stronger than mostValuation: pricier than most

A stronger business than most health care companies, priced above most of them.

Idexx Laboratories trades at 35.1 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +12.8% vs +7.8%
  • Keeps less of each sale (gross margin): 62.4% vs 65.3%
  • More profitable (operating margin): 32.0% vs 13.3%
  • Turns more of its sales into cash: 27.5% vs 15.9%
IDXX trades at 35.1x forward earnings, above the sector medianForward p/e, Health Care Equipment peers
BSX13.8xBDX15.0xMDT16.1xSYK18.4xABT18.6xEW29.3xIDXX35.1xISRG37.5xSector median 19.1xBSX13.8xBDX15.0xMDT16.1xSYK18.4xABT18.6xEW29.3xIDXX35.1xISRG37.5xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 38.8x earnings, IDXX is cheaper than its average since Aug 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
50x60xAverage 45.8x2025202638.8x50x60xAverage 45.8x2025202638.8x
Source: Nasdaq prices; SEC filings

Financials

From Idexx Laboratories's SEC filings, through the quarter ending 30 Jun 2026. Hover or tap a bar for its value.

Revenue grew 9.7% from a year earlierQuarterly revenue, $bn, latest Q2 ’26
$0.0bn$0.5bn$1.0bnQ3 ’24Q1 ’25Q3 ’25$1.2bnQ2 ’26$0.0bn$0.5bn$1.0bnQ3 ’24Q1 ’25Q3 ’25$1.2bnQ2 ’26
Source: SEC filings
Growth slowed to +9.7% last quarterRevenue growth, year on year, %
0%5%10%Q3 ’24Q1 ’25Q3 ’259.7%Q2 ’260%5%10%Q3 ’24Q1 ’25Q3 ’259.7%Q2 ’26
Source: SEC filings
Operating margin was 35.0% last quarterOperating income as a share of revenue, %
0%10%20%30%Q3 ’24Q1 ’25Q3 ’2535.0%Q2 ’260%20%Q3 ’24Q1 ’25Q3 ’2535.0%Q2 ’26
Source: SEC filings
Free cash flow was $1.3 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
$0m$100m$200m$300mQ3 ’24Q1 ’25Q3 ’25$323mQ2 ’26$0m$200mQ3 ’24Q1 ’25Q3 ’25$323mQ2 ’26
Source: SEC filings
Last 12 monthsIDXXSector median
Revenue growth+12.8%+7.8%
Gross margin62.4%65.3%
Operating margin32.0%13.3%
Free cash flow margin27.5%15.9%
Price to earnings38.7x30.2x

Similar companies

Health Care Equipment, by market value.

CompanyPriceTodayYTDValue
ABTAbbott Laboratories$106.20+1.56%−15.2%$184B
ISRGIntuitive Surgical$432.01−3.73%−23.7%$150B
MDTMedtronic$96.54−0.59%+0.5%$123B
SYKStryker$291.86−6.38%−17.0%$112B
BSXBoston Scientific$41.98−1.66%−56.0%$60.84B
BDXBecton Dickinson$197.88−0.23%+27.4%$53.90B
EWEdwards Lifesciences$92.01−2.57%+7.9%$53.03B
GEHCGE HealthCare$76.57+0.20%−6.6%$34.62B